Cancer Evolution during Immunotherapy

M C Andrews; J A Wargo

doi:10.1016/j.cell.2017.10.027

Cancer Evolution during Immunotherapy

Cell. 2017 Nov 2;171(4):740-742. doi: 10.1016/j.cell.2017.10.027.

Authors

M C Andrews¹, J A Wargo²

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jwargo@mdanderson.org.

Abstract

Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.

Publication types

Comment

MeSH terms

Humans
Immunity
Immunotherapy
Melanoma*
Nivolumab*
Programmed Cell Death 1 Receptor
Tumor Microenvironment

Substances

Programmed Cell Death 1 Receptor
Nivolumab

Grants and funding

K08 CA160692/CA/NCI NIH HHS/United States